Phaarmasia
89.35
-0.39(-0.43%)
Market Cap₹61.03 Cr
PE Ratio3.45
IndustryHealthcare
Company Performance:
1D-0.43%
1M-12.52%
6M+166.96%
1Y+196.35%
5Y+112.74%
View Company Insightsright
More news about Phaarmasia
13Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Up 26.6% QoQ, Net Profit Rebounds
Phaarmasia Limited announced Q1 FY2026 results with revenue from operations at Rs 687.36 lakhs, up 26.6% QoQ. The company reported a net profit of Rs 27.02 lakhs, compared to a loss in the previous quarter. Total income reached Rs 718.88 lakhs, with total expenses at Rs 687.58 lakhs. EPS for the quarter was Rs 0.40. The company maintained its paid-up equity share capital at Rs 682.70 lakhs and reported zero outstanding loans or debt securities.
 no imag found
11Aug 25
Phaarmasia Limited Reports Q1 FY2026 Results: Revenue Declines 17.1% YoY, Shows Sequential Improvement
Phaarmasia Limited's Q1 FY2026 results show a 17.1% year-over-year revenue decline to Rs. 687.36 lakhs, but a 26.6% sequential increase from Q4 FY2025. Net profit marginally decreased by 2.2% YoY to Rs. 27.02 lakhs. The company returned to profitability after a loss in the previous quarter. Total expenses decreased by 16.1% YoY, helping to mitigate the impact of lower revenue. EPS remained stable at Rs. 0.40.
 no imag found
Phaarmasia
89.35
-0.39
(-0.43%)
1 Year Returns:+196.35%
Industry Peers
Sun Pharmaceutical
1,878.20
(+0.81%)
Divis Laboratories
6,760.50
(-2.33%)
Torrent Pharmaceuticals
4,405.70
(+0.04%)
Cipla
1,432.10
(-0.32%)
Dr Reddys Laboratories
1,336.70
(+2.54%)
Lupin
2,276.20
(+0.80%)
Mankind Pharma
2,503.00
(+1.66%)
Zydus Life Science
1,011.70
(+2.02%)
Aurobindo Pharma
1,511.80
(+0.06%)
Laurus Labs
1,323.60
(+0.62%)